Top Class Actions Businesses Should Watch in 2026

In our previous blog, we outlined the core categories of class actions where MCAG focuses its filing and recovery efforts. As we head into 2026, this follow-up highlights the specific cases within those categories that continue to warrant close attention.

Our Research team reviews daily federal docket activity and tracks cases throughout their lifecycle. We focus on matters that show real momentum, affect broad segments of industry, and have practical relevance for our clients. The cases below provide a high-level snapshot of where our attention remains focused into the new year. This overview isn’t meant to be exhaustive; it highlights a selection of newer and ongoing cases that are currently top of mind for our team.

Product & Antitrust Litigation

Product-based antitrust cases remain one of the most consistent sources of recoveries across industries, where alleged coordination or exclusionary conduct may have inflated prices paid for goods over extended periods.

Key Matters We’re Monitoring

Food & Agriculture

• In re: Shell Eggs Antitrust Litigation (recently centralized as an MDL)

• In re: Granulated Sugar Antitrust Litigation

• In re: Frozen Potato Products Antitrust Litigation

• Protein Markets (Turkey, Beef, Pork)

Construction

• In re: Construction Rental Equipment Antitrust Litigation-alleges that major equipment rental companies conspired to raise and stabilize prices for machinery such as forklifts and excavators, since 2021.

Healthcare Litigation

Healthcare continues to generate some of the largest and most complex recovery opportunities. Many of these cases center on alleged systematic underpayment, repricing methodologies, or network manipulation. The impact can be significant for hospitals, facilities, and provider groups.

Key Matters We’re Monitoring:

PBMs & Pricing Intermediaries

• GoodRx & Pharmacy Benefit Manager Antitrust Litigation – claims tied to PBM pricing practices and the use of data within prescription drug markets.

Repricing & Network Manipulation

• In re: MultiPlan Health Insurance Provider Litigation – allegations of systematic underpayment through repricing schemes.

• Zelis Repricing Litigation – emerging cases focused on similar repricing and network-based conduct.

Pharmaceutical Litigation

Pharmaceutical class actions often stem from allegations involving pricing strategies, market entry delays, or distribution and rebate structures that may have increased costs for payors and health plans over time.

Key Matter’s We’re Monitoring:

Core MDLs

• In re: Insulin Pricing Litigation (MDL 3080) – consolidated actions alleging coordinated conduct between the nation’s three largest insulin manufacturers and three major pharmacy benefit managers to increase the cost of insulin.

• In re: Generic Pharmaceuticals Pricing Antitrust Litigation (MDL 2724) – active across multiple class tracks, MCAG continues to monitor the end-payor and health plan track as the claims process tied to $533 million in settlements approaches.

Anticipated or Incoming Settlements

• QVAR RediHaler Settlement – $35 million settlement; claims process and filing deadline have not yet been announced.

• Sartan Settlement –  $17 million settlement; claims process and filing deadline have not yet been announced.

Emerging & Newly Filed Matters

• Insulin & GLP-1 Drugs / Safety Net Hospitals – alleges restrictions on 340B discounts beginning in 2020 through a horizontal price-fixing conspiracy.

• Xifaxan – antibiotic used to treat IBS-D and hepatic encephalopathy treatment.

• Vivitrol – injectable medication for alcohol and opioid dependence.

• Respimat – therapy used for long-term asthma management.

• Entresto – medication for chronic heart failure.

• GLP-1 drugs, including Victoza

Financial & Payment Processing

Payment processing litigation continues to be a meaningful area of recovery for merchants. Many of these cases focus on how cost, risk, or operational restrictions were shifted downstream by card networks or issuers.

Key Matter’s We’re Monitoring

• Fraud Liability Shift Antitrust Litigation —a settlement has been reached for merchants. MCAG is monitoring for the opening of the claims process tied to  $231 million.

• In re: Visa Debit Interchange Fee Antitrust Litigation (MDL) —ongoing litigation alleging anti-competitive debit interchange practices.

• American Express Anti-Steering Rules Litigation—Merchant claims ongoing

What We’re Filing Now — and What’s Coming Next

MCAG continues to actively file and monitor claims across antitrust, healthcare, and complex commercial settlements. For current opportunities and deeper analysis, see our recent posts:

• Discover Card Merchant Settlement ($1.2 billion)– claims deadline May 18, 2026(Unlock Discover — Here’s What You Need to Know)

  
  

• Fraud Liability Shift Settlement – monitoring for claims process and deadline ($231.7 million)(Fraud Liability Shift Settlement)

  
  

• Acute Care Hospital Opioids Settlement – new filing round anticipated, monitoring for approval and claims filing to open ($174 million)(Acute Care Hospital Opioids Settlement)

  
  

• Generic Pharmaceutical End Payor Settlement – monitoring for claims filing to open ($533 million)(Generic Pharmaceuticals Pricing Antitrust Litigation)

Staying Ahead in 2026

The most impactful settlements often take years to unfold, and the businesses that recover the most are those paying attention early.

As 2026 approaches, MCAG continues to help clients identify opportunities, assess eligibility, and act before value is missed. For ongoing insights and updates, follow the MCAG Settlement News Blog.

Settlement figures referenced above are estimates and may change based on court approval, allocation methodology, and settlement administration.